gefitinib has been researched along with tridemorph in 1 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (tridemorph) | Trials (tridemorph) | Recent Studies (post-2010) (tridemorph) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 997 | 7 | 301 |
Protein | Taxonomy | gefitinib (IC50) | tridemorph (IC50) |
---|---|---|---|
Cycloeucalenol cycloisomerase | Zea mays | 0.4 | |
Sterol-8,7-isomerase | Zea mays | 0.4 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Antonaci, S; Azzariti, A; Fransvea, E; Giannelli, G; Paradiso, A; Porcelli, L | 1 |
1 other study(ies) available for gefitinib and tridemorph
Article | Year |
---|---|
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Kalinin; Phosphorylation; Predictive Value of Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |